Cargando…

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

Objective: The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for stro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubio-Terrés, Carlos, Graefenhain de Codes, Ruth, Rubio-Rodríguez, Darío, Evers, Thomas, Grau Cerrato, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2016
Materias:	Cardiovascular Conditions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471359/ https://www.ncbi.nlm.nih.gov/pubmed/37663009 http://dx.doi.org/10.36469/9823

Ejemplares similares

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
por: Granero Xiberta, Xavier, et al.
Publicado: (2016)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
por: Khaykin, Yaariv, et al.
Publicado: (2016)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation
por: Reynolds, Matthew R., et al.
Publicado: (2014)

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
por: Peacock, W. Frank, et al.
Publicado: (2019)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
por: Aguiar, Carlos, et al.
Publicado: (2022)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
por: Colet, Josep Comín, et al.
Publicado: (2023)

Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study)
por: Dalmau Llorca, M. Rosa, et al.
Publicado: (2021)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Spontaneous spinal epidural hematoma in a patient on acenocoumarol for valvular atrial fibrillation: A rare case report
por: El-azrak, Mohammed, et al.
Publicado: (2021)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis
por: Yang, Zhenzhen, et al.
Publicado: (2023)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

The Cost of an Operating Room Minute for Heart Valve Procedures
por: Grossi, Eugene A., et al.
Publicado: (2015)

An Algorithm to Analyze Cost Heterogeneity using Counterfactual Scenarios in Endovascular versus Open Repair of Abdominal Aortic Aneurysm: Predicting Costs for Subsequent Patients
por: Jones, Christopher A., et al.
Publicado: (2014)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey
por: Arnold, Renée JG, et al.
Publicado: (2015)

The Cost Effectiveness of Hand Held Ultrasound Scanning for Abdominal Aortic Aneurysm in Older Males with a History of Smoking
por: Phiri, Denver, et al.
Publicado: (2013)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States
por: Blanchette, Christopher M., et al.
Publicado: (2017)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
por: Ruiz, George, et al.
Publicado: (2018)

Real-world Bleeding Outcomes and Costs Following Vascular Graft Anastomosis Using PROLENE Sutures with HEMO-SEAL Technology in Patients Undergoing Abdominal Aortic Aneurysm Repair
por: Sutton, Nadia Y., et al.
Publicado: (2017)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

The Association of Economic Outcome and Geriatric Syndromes among Older Adults with Transcatheter Aortic Valve Replacement (TAVR)
por: Kwak, Min Ji, et al.
Publicado: (2020)

Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
por: Kodama, Kazuhisa, et al.
Publicado: (2020)

Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism
por: Wang, Li, et al.
Publicado: (2019)

A Systematic Literature Review of Three Stenting Strategies for Bifurcation Lesions in Coronary Artery Disease
por: Parsley-Raines, Larragem, et al.
Publicado: (2019)

Sternal-Wound Infections following Coronary Artery Bypass Graft: Could Implementing Value-Based Purchasing be Beneficial?
por: Brandt, Dominique, et al.
Publicado: (2020)

Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
por: Berger, Ariel, et al.
Publicado: (2014)

Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
por: Han, Xue, et al.
Publicado: (2022)

The Association of COPD Exacerbations with New Onset Type 2 Diabetes among Medicare Patients
por: Marino, Joseph S., et al.
Publicado: (2017)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Cardiovascular Disease and Its Implication for Higher Catastrophic Health Expenditures Among Households in Sub-Saharan Africa
por: Adeniji, Folashayo Ikenna Peter, et al.
Publicado: (2023)

New Oral Anaticoagulant Prescribing Decisions amongst General Practitioners: Handle with Care
por: Kirby, Ann, et al.
Publicado: (2017)

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation
por: Korenstra, Jennie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6u6bcpa4udm8od19r0anfbgr6p